Can serum angiogenin be used to improve the diagnostic performance in prostate cancer screening?

Pina, Francisco; Botelho, Francisco; Lopes, Teresa da Silva; Lopes, Igor A. Rodrigues; Figueiredo, G.; Portugal, Raquel; Ferro, Ana; Cruz, Francisco; Barros, Henrique; Lunet, Nuno

doi:10.1097/cej.0b013e3283647453

Cited by 8 publications

(6 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Various malignant carcinomas, including prostatic cancer, depend on angiogenesis for growth, invasion, and progression. Pina et al [ 67 ] evaluated the serum levels of ANG as a diagnostic marker in the 252 patients who had prostate cancer. They noted that the median serum ANG levels were significantly higher in prostate cancer patients ( p = 0.008).…”

Section: Discussionmentioning

confidence: 99%

Urinary Angiogenin as a Marker for Bladder Cancer: A Meta-Analysis

Aalami

Abdeahad

Mesgari

et al. 2021

BioMed Research International

View full text Add to dashboard Cite

Aims. Bladder cancer (BCa) is a common cancer in North America and Europe that carries considerable morbidity and mortality. A reliable biomarker for early detection of the bladder is crucial for improving the prognosis of BCA. In this meta-analysis, we examine the diagnostic role of the angiogenin (ANG) protein in patients’ urine with bladder neoplasm. Methods. We performed a systematic literature search using ScienceDirect, Web of Science, PubMed/MEDLINE, Scopus, Google Scholar, and Embase, up to 10th October 2020 databases. Meta-Disc V.1.4 and Comprehensive Meta-Analysis V.2.2 software calculated the pooled specificity, sensitivity, area under the curve (AUC), diagnostic odds ratio (DOR), positive likelihood ratio (LR+), negative likelihood ratio (LR-), Q ∗ index, and summary receiver-operating characteristic (SROC) for the role of ANG as a urinary biomarker for BCa patients. Results. Four case-control studies were included with 656 participants (417 cases and 239 controls) in this meta-analysis. The pooled sensitivity of 0.71 (95% CI: 0.66–0.75), specificity of 0.78 (95% CI: 0.73–0.81), LR+ of 3.34 (95% CI: 2.02–5.53), LR- of 0.37 (95% CI: 0.32–0.44), DOR of 9.99 (95% CI: 4.69–21.28), and AUC of 0.789 and Q ∗ index of 0.726 demonstrate acceptable diagnostic precision of ANG in identifying BCa. Conclusion. This meta-analysis showed that ANG could be a fair biomarker for the diagnosis of BCa patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Urinary Angiogenin as a Marker for Bladder Cancer: A Meta-Analysis

Aalami

Abdeahad

Mesgari

et al. 2021

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…1 ). In prostate cancer, hRNase5/ANG was also identified as an oncogene, as shown by its role in angiogenesis, a molecular target for the treatment, and a potential diagnostic biomarker [ 73 – 75 ]. Moreover, hRNase5/ANG plays a role in epithelial-mesenchymal transition (EMT) in squamous cell lung carcinoma to promote cell proliferation, migration, and invasion capacity through direct upregulation of a non-histone chromosomal high-mobility group protein [ 76 , 77 ].…”

Section: Introductionmentioning

confidence: 99%

A novel ligand-receptor relationship between families of ribonucleases and receptor tyrosine kinases

2018

View full text Add to dashboard Cite

Pancreatic ribonuclease is known to participate in host defense system against pathogens, such as parasites, bacteria, and virus, which results in innate immune response. Nevertheless, its potential impact to host cells remains unclear. Of interest, several ribonucleases do not act as catalytically competent enzymes, suggesting that ribonucleases may be associated with certain intrinsic functions other than their ribonucleolytic activities. Most recently, human pancreatic ribonuclease 5 (hRNase5; also named angiogenin; hereinafter referred to as hRNase5/ANG), which belongs to the human ribonuclease A superfamily, has been demonstrated to function as a ligand of epidermal growth factor receptor (EGFR), a member of the receptor tyrosine kinase family. As a newly identified EGFR ligand, hRNase5/ANG associates with EGFR and stimulates EGFR and the downstream signaling in a catalytic-independent manner. Notably, hRNase5/ANG, whose level in sera of pancreatic cancer patients, serves as a non-invasive serum biomarker to stratify patients for predicting the sensitivity to EGFR-targeted therapy. Here, we describe the hRNase5/ANG-EGFR pair as an example to highlight a ligand-receptor relationship between families of ribonucleases and receptor tyrosine kinases, which are thought as two unrelated protein families associated with distinct biological functions. The notion of serum biomarker-guided EGFR-targeted therapies will also be discussed. Furthering our understanding of this novel ligand-receptor interaction will shed new light on the search of ligands for their cognate receptors, especially those orphan receptors without known ligands, and deepen our knowledge of the fundamental research in membrane receptor biology and the translational application toward the development of precision medicine.

show abstract

“…High serum levels of angiogenin were observed in patients with divergent cancers, including pancreatic cancer [39], colorectal cancer [37], bladder carcinoma [48], melanoma [49], B non-Hodgkin lymphoma [50], and prostate cancer [51], but to our knowledge, no previous studies addressed this issue in breast cancer. We demonstrated that serum ANG level of breast cancer patients was significantly higher than that of healthy donors.…”

Section: Discussionmentioning

confidence: 96%